Considering its role in regulating EGFR signaling, ANXA1 may be a novel therapeutic target, and targeting ANXA1 combined with EGFR inhibitors may be a new treatment strategy for BLCA patients with high ANXA1 expression. Here, EGFR is linked to bladder transitional cell carcinoma.